Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Venetoclax plus HMA studied in AML

DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

Publish date:: November 9, 2018

Key clinical point: Venetoclax with a hypomethylating agent was safe and effective as first-line therapy for older adults with AML who were ineligible for standard induction chemotherapy.

Major finding: At a median time of study of 8.9 months, the overall response rate among all treated patients was 68%.

Study details: Follow-up of a phase 1b dose-escalation and expansion cohort of 145 patients aged 65 years and older with treatment-naive AML.

Disclosures: The trial was supported by AbbVie and Genentech. Dr. DiNardo and multiple coauthors disclosed relationships with AbbVie, Genentech, and other companies.

Read the article.

Citation:

DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in AML

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release